Half-Life Visualizer
Published encyclopedia entries with chartable half-life data: 68.
Interactive plasma half-life decay charts and pharmacokinetic references for research compounds with chartable data. For each compound, the visualizer shows a plasma-concentration decay curve alongside plasma half-life, duration of active effect, bioavailability by administration route, steady-state timing, and washout period.
What is plasma half-life and why does it matter?
Plasma half-life (t½) is the time required for compound concentration in blood plasma to fall by 50%. Published study parameters use this measure to describe concentration profiles and study duration; findings vary by compound and research method.
Compounds covered
The visualizer includes pharmacokinetic data for the following compound categories and specific peptides:
- Regenerative & Repair: BPC-157, TB-500 (Thymosin Beta-4), GHK-Cu, BPC-157 & TB-500 blend
- GLP-1, GIP & Metabolic Peptides: Semaglutide, Tirzepatide, Retatrutide, Liraglutide, Dulaglutide, Oxytocin
- Growth Hormone Axis: Ipamorelin, CJC-1295, CJC-1295 DAC, GHRP-2, GHRP-6, Hexarelin, Tesamorelin, Sermorelin, MK-677 (Ibutamoren)
- Nootropic & Cognitive: Selank, Semax, Dihexa, Epithalon, P21
- Melanocortin & Sexual Function: PT-141 (Bremelanotide), Melanotan II
- Immune Modulating: Thymosin Alpha-1 (Tα1), LL-37
- Longevity & Mitochondrial: SS-31 (Elamipretide), MOTS-c, Humanin, NAD+
- Amino Acids & Antioxidants: Glutathione, L-Glutamine, Taurine, L-Carnitine, NAC
- Hormonal & Reproductive: HCG, Kisspeptin-10
- Khavinson Bioregulators: Epithalon, Pinealon, Vilon, Thymalin, Cortexin, Vesugen, Testagen, Chonluten, Sigumir, Bonomarlot, Ventfort, Crystagen, Libidon, Endoluten, Cartalax, Gotratix
- Small Molecules & Metabolic: AOD-9604, 5-Amino-1MQ, Methylene Blue
- Anti-Cancer Research: IGF-1 LR3
- Cosmetic & Skin: SNAP-8, Leuphasyl
How to use the Half-Life Visualizer
Search or browse the compound list on the left to select any peptide. The visualizer renders its plasma decay curve with reference lines marking the half-life point (50% remaining, amber) and the approximate washout point (~97% cleared, red). Below the chart, stat cards show duration of active effect, bioavailability by administration route, steady-state timing, and washout period. Use Compare Mode to plot two compounds on the same time axis side by side.
Understanding the pharmacokinetic stats
- Duration of Active Effect
- The window during which the compound is expected to exert a meaningful biological effect, distinct from plasma half-life when downstream effects outlast plasma clearance, as with Khavinson bioregulators.
- Bioavailability by Route
- How much of the compound reaches systemic circulation through a route of administration: subcutaneous (SC), intramuscular (IM), intravenous (IV), intranasal, or oral. Most peptides are poorly bioavailable orally due to GI degradation.
- Steady-State Timing
- The time for plasma levels to reach a steady state across repeated study intervals. The timing depends on the compound and reported research method.
- Washout Period
- The time required for the compound to clear sufficiently from the system, approximately 5 half-lives for most compounds. At that point, less than 3% remains in plasma.
Khavinson bioregulator note
Khavinson bioregulators (Epithalon, Pinealon, Vilon, Thymalin, and related short peptides) have plasma half-lives measured in minutes but trigger gene-expression changes that persist for weeks to months. The decay chart shows plasma clearance only. The biologically relevant duration is the gene-expression effect window shown in the stat cards.